Adcock Ingram Holdings (JSE:AIP) ROCE % : 22.19% (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Adcock Ingram Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adcock Ingram Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was 22.19%.

Adcock Ingram Holdings ROCE % Historical Data

The historical data trend for Adcock Ingram Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adcock Ingram Holdings ROCE % Chart

Adcock Ingram Holdings Annual Data

Trend

Sep13

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

23.25

20.60

18.96

21.30

21.94

Adcock Ingram Holdings Semi-Annual Data
	Mar14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															21.74	20.87	22.83	20.50	22.19

Adcock Ingram Holdings ROCE % Calculation

Adcock Ingram Holdings's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	1265.246	/	( ( (7889.162 - 2186.337)	+	(8262.534 - 2434.209) )	/ 2 )
	=	1265.246	/	( (5702.825	+	5828.325)	/ 2 )
	=	1265.246	/	5765.575
	=	21.94 %

Adcock Ingram Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	1299.754	/	( ( (8262.534 - 2434.209)	+	(8329.023 - 2444.775) )	/ 2 )
	=	1299.754	/	( ( 5828.325	+	5884.248 )	/ 2 )
	=	1299.754	/	5856.2865
	=	22.19 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Adcock Ingram Holdings (JSE:AIP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adcock Ingram Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Adcock Ingram Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adcock Ingram Holdings (JSE:AIP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adcock Ingram Holdings Ltd (JSE:AIP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 New Road, (c/o New Road & 7th Street), Midrand, Johannesburg, GT, ZAF, 1682

Website

https://www.adcock.com

Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.